Putative cancer stem cells (CD133+/EpCAM+) are eliminated from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal Phase II/III studyH. Lindhofer, A. Schoberth, D. Pelster,J. Hess, J. Herold, M. Stroehlein,M. JaegerONKOLOGIE（2010）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
